Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

NCT01471717 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: INX-08189 50 mg QD X 5 days
DRUG: INX-08189 / Victrelis 800 mg TID X three days
DRUG: Victrelis 800 mg TID x 3 days
DRUG: Victrelis 800 mg TID with INX-08189 50 mg QD
DRUG: Placebo with Victrelis 800 mg
DRUG: Cohort 2: Victrelis 800 mg with Placebo

Sponsor

Bristol-Myers Squibb